The commercial prospects of biogenerics – how much will they save?
This follow-up to my post on the technical reasons why biogenerics are so hard to regulate provides some updates the status of biogenerics, background on the key issues, and the impacts on the industry of the various possible approval schemes. Clinical Trials The clinical trial requirement for biogenerics is the leading issue from a regulatory […]